DexCom's stock narrative has shifted as analysts lower their fair value estimate from $98.40 to $84.96, marking a significant downward revision in the price target. This adjustment is primarily driven ...
Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.
According to Diabète Québec, type 2 diabetes is the most common form, affecting nearly 90% of those living with diabetes, and many eventually require insulin when lifestyle changes and oral ...
StockStory.org on MSN
The 5 Most Interesting Analyst Questions From DexCom’s Q3 Earnings Call
DexCom's third quarter was met with a negative market reaction despite outpacing Wall Street’s revenue and adjusted EPS ...
Zacks Investment Research on MSN
DexCom Stock Falls Despite Q3 Earnings Beat, 2025 Revenue View Raised
DexCom, Inc. DXCM reported third-quarter 2025 adjusted earnings per share (EPS) of 61 cents, which beat the Zacks Consensus ...
DXCM's Q3 results are likely to benefit from rising G7 use, early Stelo traction and expanding access across Type 2 diabetes markets.
Thank you, operator, and welcome to DexCom's Third Quarter 2025 Earnings Call. Our agenda begins with Jake Leach, DexCom's President and Interim CEO, who will summarize our recent highlights and ...
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ:DXCM) securities during ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback